Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accounts Payables: 2009-2025

Historic Accounts Payables for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $22.1 million.

  • Cytokinetics' Accounts Payables rose 90.69% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 90.69%. This contributed to the annual value of $20.4 million for FY2024, which is 5.29% down from last year.
  • Per Cytokinetics' latest filing, its Accounts Payables stood at $22.1 million for Q3 2025, which was up 36.09% from $16.2 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Accounts Payables registered a high of $25.6 million during Q4 2022, and its lowest value of $7.8 million during Q1 2021.
  • In the last 3 years, Cytokinetics' Accounts Payables had a median value of $13.9 million in 2025 and averaged $15.6 million.
  • As far as peak fluctuations go, Cytokinetics' Accounts Payables soared by 411.23% in 2021, and later dropped by 25.29% in 2024.
  • Quarterly analysis of 5 years shows Cytokinetics' Accounts Payables stood at $21.1 million in 2021, then climbed by 21.45% to $25.6 million in 2022, then decreased by 16.02% to $21.5 million in 2023, then fell by 5.29% to $20.4 million in 2024, then skyrocketed by 90.69% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $16.2 million for Q2 2025, and $13.9 million during Q1 2025.